Skip to content

Studying the role of probiotics for the treatment of early stage of cervical cancer in Bangladesh

Studying the role of probiotics as potential biotherapeutics for cervical intraepithelial neoplasia

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034616
Enrollment
100
Registered
2021-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N870- Mild cervical dysplasia

Interventions

Intervention1: Probiotics: Lactobacillus acidophilus (2 billion), Lactobacillus bulgaricus (1 billion), Bifidobactaterium bifidum (1 billion), and Fructooligosaccharides (100 mg) Dose with duration

Sponsors

BANBEIS Ministry of Education
Lead Sponsor
Purnava Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Female Age: 18 -45 years Non-pregnant Willing to take conservative treatment and colposcopy (if required) Not taking antibiotics, probiotics, vitamins and other medications for any other co morbidity within one month before participating in this research work. Women irrespective of their ethnicity, parity, phase in their cycle and use of contraception, Smoking, alcohol consumption habits. Women with a diagnosis of LSIL on their latest PAP smear Women with a first as well as with a repeat LSIL diagnosis

Exclusion criteria

Exclusion criteria: Age: female below 18 years and above 45 years Pregnant Not willing to take conservative treatment and colposcopy (if required) Taking antibiotics, probiotics, vitamins and other medications for any other co morbidity within one month before participating in this research work. Women with a previous history of cervical treatment Women with HIV or hepatitis B/C positive with autoimmune diseases Patients suffering from invasive cervical cancer

Design outcomes

Primary

MeasureTime frame
absence or decrease the severity of clinical signs-symptoms.Timepoint: Day 0, day 180

Secondary

MeasureTime frame
The change in vaginal microbiotia (composition, abundance and diversity). Lactobacillus level of all groups Detection of HPV of patients adverse eventsTimepoint: Day 0 and Day 180

Countries

Bangladesh

Contacts

Public ContactAbu Syed Md Mosaddek

Quest Bangladesh,

Drmosaddek1968@gmail.com01711483814

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026